The tuberous sclerosis complex genes in tumor development

Cancer Investigation

Volumn 22, Issue 4, 2004, Pages 588-603

  Mak, Baldwin C ^a   Yeung, Raymond S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cantenin; LKB1; MTOR; Protein transport; PTEN; Rapamycin; TSC1; TSC2

Indexed keywords

FLAVOPIRIDOL; GENE PRODUCT; HAMARTIN; MITOGEN ACTIVATED PROTEIN KINASE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; TUBERIN;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; COWDEN SYNDROME; ENDOMETRIUM CANCER; FAMILIAL POLYPOSIS; GENE; GENE INACTIVATION; HAMARTOMA; HUMAN; LUNG CANCER; NONHUMAN; PEUTZ JEGHERS SYNDROME; PHAKOMATOSIS; PRIORITY JOURNAL; PROSTATE CANCER; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; TUMOR GROWTH;

BIOLOGICAL TRANSPORT; CELL PROLIFERATION; CELL SIZE; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 8644274532     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200027144     Document Type: Article

References (116)

1. Knudson, A.G. Two genetic hits (more or less) to cancer. Nat. Rev., Cancer 2001, 1, 157-162.
2. Knudson, A.G. Chasing the cancer demon. Annu. Rev. Genet. 2000, 34, 1-19.
3. Bourneville, D.M. Sclérose tubéreuse des circonvolutions cérébrales: idiotie et épilepsie hémiplé gique. Arch. Neurol. (Paris) 1880, 1, 81-91.
4. Gomez, M.R. Definition and criteria for diagnosis. In Tuberous Sclerosis Complex; Gomez, M.R., Sampson, J.R., Whittemore, V.H., Eds.; Oxford University Press: New York, 1999; 10-23.
5. Shepherd, C.W.; Beard, C.M.; Gomez, M.R.; Kurland, L.T.; Whisnant, J.P. Tuberous sclerosis complex in Olmsted County, Minnesota, 1950-1989. Arch. Neurol. 1991, 48, 400-401.
6. Webb, D.W.; Fryer, A.E.; Osborne, J.P. Morbidity associated with tuberous sclerosis: a population study. Dev. Med. Child Neurol. 1996, 38, 146-155.
7. Crino, P.B.; Trojanowski, J.Q.; Dichter, M.A.; Eberwine, J. Embryonic neuronal markers in tuberous sclerosis: single-cell molecular pathology. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 14152-14157.
8. Hirose, T.; Scheithauer, B.W.; Lopes, M.B.; Gerber, H.A.; Altermatt, H.J.; Hukee, M.J.; VandenBerg, S.R.; Charlesworth, J.C. Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis: an immunohistochemical, ultrastructural, and immunoelectron and microscopic study. Acta. Neuropathol. (Berl) 1995, 90, 387-399.
9. Bjornsson, J.; Short, M.P.; Kwiatkowski, D.J.; Henske, E.P. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am. J. Pathol. 1996, 149, 1201-1208.
10. Yu, J.; Astrinidis, A.; Henske, E.P. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am. J. Respir. Crit. Care Med. 2001, 164, 1537-1540.
11. van Slegtenhorst, M.; de Hoogt, R.; Hermans, C.; Nellist, M.; Janssen, B.; Verhoef, S.; Lindhout, D.; van den Ouweland, A.; Halley, D.; Young, J.; et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277, 805-808.
12. Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Consortium. Cell 1993, 75, 1305-1315.
13. Brook-Carter, P.T.; Peral, B.; Ward, C.J.; Thompson, P.; Hughes, J.; Maheshwar, M.M.; Nellist, M.; Gamble, V.; Harris, P.C.; Sampson, J.R. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease-a contiguous gene syndrome. Nat. Genet. 1994, 8, 328-332.
14. Harris, P.C. The TSC2/PKD1 contiguous gene syndrome. Contrib. Nephrol. 1997, 122, 76-82.
15. Dabora, S.L.; Jozwiak, S.; Franz, D.N.; Roberts, P.S.; Nieto, A.; Chung, J.; Choy, Y.S.; Reeve, M.P.; Thiele, E.; Egelhoff, J.C.; et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 2001, 68, 64-80.
16. Jones, A.C.; Shyamsundar, M.M.; Thomas, M.W.; Maynard, J.; Idziaszczyk, S.; Tomkins, S.; Sampson, J.R.; Cheadle, J.P. Comprehensive mutation analysis of TSC1 and TSC2 and phenotypic correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet. 1999, 64, 1305-1315.
17. Verhoef, S.; Bakker, L.; Tempelaars, A.M.; Hesseling-Janssen, A.L.; Mazurczak, T.; Jozwiak, S.; Fois, A.; Bartalini, G.; Zonnenberg, B.A.; van Essen, A.J.; et al. High rate of mosaicism in tuberous sclerosis complex. Am. J. Hum. Genet. 1999, 64, 1632-1637.
18. Yates, J.R.; van Bakel, I.; Sepp, T.; Payne, S.J.; Webb, D.W.; Nevin, N.C.; Green, A.J. Female germline mosaicism in tuberous sclerosis confirmed by molecular genetic analysis. Hum. Mol. Genet. 1997, 6, 2265-2269.
19. Green, A.J.; Johnson, P.H.; Yates, J.R. The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum. Mol. Genet. 1994, 3, 1833-1834.
20. Henske, E.P.; Wessner, L.L.; Golden, J.; Scheithauer, B.W.; Vortmeyer, A.O.; Zhuang, Z.; Klein-Szanto, A.J.; Kwiatkowski, D.J.; Yeung, R.S. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am. J. Pathol. 1997, 151, 1639-1647.
21. Hengstschlager, M.; Rodman, D.M.; Miloloza, A.; Hengstschlager-Ottnad, E.; Rosner, M.; Kubista, M. Tuberous sclerosis gene products in proliferation control. Mutat. Res. 2001, 488, 233-239.
22. Han, S.; Santos, T.M.; Puga, A.; Roy, J.; Thiele, E.A.; McCollin, M.; Stemmer-Rachamimov, A.; Ramesh, V. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res. 2004, 64, 812-816.
23. Plank, T.L.; Yeung, R.S.; Henske, E.P. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res. 1998, 58, 4766-4770.
24. van Slegtenhorst, M.; Nellist, M.; Nagelkerken, B.; Cheadle, J.; Snell, R.; van den Ouweland, A.; Reuser, A.; Sampson, J.; Halley, D.; van der Sluijs, P. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet. 1998, 7, 1053-1057.
25. Potter, C.J.; Huang, H.; Xu, T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001, 105, 357-368.
26. Hodges, A.K.; Li, S.; Maynard, J.; Parry, L.; Braverman, R.; Cheadle, J.P.; DeClue, J.E.; Sampson, J.R. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum. Mol. Genet. 2001, 10, 2899-2905.
27. Nellist, M.; van Slegtenhorst, M.A.; Goedbloed, M.; van den Ouweland, A.M.; Halley, D.J.; van der Sluijs, P. Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin. J. Biol. Chem. 1999, 274, 35647-35652.
28. Yamamoto, Y.; Jones, K.A.; Mak, B.C.; Muehlenbachs, A.; Yeung, R.S. Multicompartmental distribution of the tuberous sclerosis gene products, hamartin and tuberin. Arch. Biochem. Biophys. 2002, 404, 210-217.
29. Aicher, L.D.; Campbell, J.S.; Yeung, R.S. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis. J. Biol. Chem. 2001, 276, 21017-21021.
30. Nellist, M.; Verhaaf, B.; Goedbloed, M.A.; Reuser, A.J.; van den Ouwel, A.M.; Halley, D.J. TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum. Mol. Genet. 2001, 10, 2889-2898.
31. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4, 648-657.
32. Olsson, P.G.; Schofield, J.N.; Edwards, Y.H.; Frischauf, A.M. Expression and differential splicing of the mouse TSC2 homolog. Mamm. Genome 1996, 7, 212-215.
33. Murthy, V.; Haddad, L.A.; Smith, N.; Pinney, D.; Tyszkowski, R.; Brown, D.; Ramesh, V. Similarities and differences in the subcellular localization of hamartin and tuberin in the kidney. Am. J. Physiol., Renal Physiol. 2000, 278, F737-F746.
34. Wienecke, R.; Maize, J.C., Jr.; Reed, J.A.; de Gunzburg, J.; Yeung, R.S.; DeClue, J.E. Expression of the TSC2 product tuberin and its target Rap1 in normal human tissues. Am. J. Pathol. 1997, 150, 43-50.
35. Jones, K.A.; Jiang, X.; Yamamoto, Y.; Yeung, R.S. Tuberin is a component of lipid rafts and mediates caveolin-1 localization: role of TSC2 in post-Golgi transport. Exp. Cell Res. 2004, 295, 512-524.
36. Lou, D.; Griffith, N.; Noonan, D.J. The tuberous sclerosis 2 gene product can localize to nuclei in a phosphorylation-dependent manner. Mol. Cell. Biol. Res. Commun. 2001, 4, 374-380.
37. Catania, M.G.; Mischel, P.S.; Vinters, H.V. Hamartin and tuberin interaction with the G2/M cyclin-dependent kinase CDK1 and its regulatory cyclins A and B. J. Neuropathol. Exp. Neurol. 2001, 60, 711-723.
38. Gao, X.; Pan, D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001, 15, 1383-1392.
39. Potter, C.J.; Xu, T. Mechanisms of size control. Curr. Opin. Genet. Dev. 2001, 11, 279-286.
40. Potter, C.J.; Pedraza, L.G.; Xu, T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 2002, 4, 658-665.
41. Gao, X.; Zhang, Y.; Arrazola, P.; Hino, O.; Kobayashi, T.; Yeung, R.S.; Ru, B.; Pan, D. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 2002, 4, 699-704.
42. Goncharova, E.A.; Goncharov, D.A.; Eszterhas, A.; Hunter, D.S.; Glassberg, M.K.; Yeung, R.S.; Walker, C.L.; Noonan, D.; Kwiatkowski, D.J.; Chou, M.M.; et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleio-myomatosis (LAM). J. Biol. Chem. 2002, 277, 30958-30967.
43. Manning, B.D.; Tee, A.R.; Logsdon, M.N.; Blenis, J.; Cantley, L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 2002, 10, 151-162.
44. Dan, H.C.; Sun, M.; Yang, L.; Feldman, R.I.; Sui, X.M.; Ou, C.C.; Nellist, M.; Yeung, R.S.; Halley, D.J.; Nicosia, S.V.; et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 2002, 277, 35364-35370.
45. Jaeschke, A.; Hartkamp, J.; Saitoh, M.; Roworth, W.; Nobukuni, T.; Hodges, A.; Sampson, J.; Thomas, G.; Lamb, R. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell. Biol. 2002, 159, 217-224.
46. Reynolds, T.H.T.; Bodine, S.C.; Lawrence, J.C., Jr. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J. Biol. Chem. 2002, 277, 17657-17662.
47. Kwiatkowski, D.J.; Zhang, H.; Bandura, J.L.; Heiberger, K.M.; Glogauer, M.; el-Hashemite, N.; Onda, H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 2002, 11, 525-534.
48. Wienecke, R.; Konig, A.; DeClue, J.E. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J. Biol. Chem. 1995, 270, 16409-16414.
49. Xiao, G.H.; Shoarinejad, F.; Jin, F.; Golemis, E.A.; Yeung, R.S. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J. Biol. Chem. 1997, 272, 6097-6100.
50. Saucedo, L.J.; Gao, X.; Chiarelli, D.A.; Li, L.; Pan, D.; Edgar, B.A. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol. 2003, 5, 566-571.
51. Stocker, H.; Radimerski, T.; Schindelholz, B.; Wittwer, F.; Belawat, P.; Daram, P.; Breuer, S.; Thomas, G.; Hafen, E. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol. 2003, 5, 559-565.
52. Zhang, Y.; Gao, X.; Saucedo, L.J.; Ru, B.; Edgar, B.A.; Pan, D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 2003, 5, 578-581.
53. Inoki, K.; Li, Y.; Xu, T.; Guan, K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 77, 1829-1834.
54. Tee, A.R.; Manning, B.D.; Roux, P.P.; Cantley, L.C.; Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 2003, 13, 1259-1268.
55. Castro, A.F.; Rebhun, J.F.; Clark, G.J.; Quilliam, L.A. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 2003, 278, 32493-32496.
56. Garami, A.; Zwartkruis, F.J.; Nobukuni, T.; Joaquin, M.; Roccio, M.; Stocker, H.; Kozma, S.C.; Hafen, E.; Bos, J.L.; Thomas, G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 2003, 11, 1457-1466.
57. Rohde, J.; Heitman, J.; Cardenas, M.E. The TOR kinases link nutrient sensing to cell growth. J. Biol. Chem. 2001, 276, 9583-9586.
58. Hara, K.; Maruki, Y.; Long, X.; Yoshino, K.; Oshiro, N.; Hidayat, S.; Tokunaga, C.; Avruch, J.; Yonezawa, K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110, 177-189.
59. Kim, D.H.; Sarbassov dos, D.; Ali, S.M.; Latek, R.R.; Guntur, K.V.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D.M. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 2003, 11, 895-904.
60. Loewith, R.; Jacinto, E.; Wullschleger, S.; Lorberg, A.; Crespo, J.L.; Bonenfant, D.; Oppliger, W.; Jenoe, P.; Hall, M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 2002, 10, 457-468.
61. Schmidt, A.; Bickle, M.; Beck, T.; Hall, M.N. The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2. Cell 1997, 88, 531-542.
62. Choi, J.H.; Adames, N.R.; Chan, T.F.; Zeng, C.; Cooper, J.A.; Zheng, X.F. TOR signaling regulates microtubule structure and function. Curr. Biol. 2000, 10, 861-864.
63. Choi, J.H.; Bertram, P.G.; Drenan, R.; Carvalho, J.; Zhou, H.H.; Zheng, X.F. The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase. EMBO Rep. 2002, 3, 988-994.
64. Dennis, P.B.; Jaeschke, A.; Saitoh, M.; Fowler, B.; Kozma, S.C.; Thomas, G. Mammalian TOR: a homeostatic ATP sensor. Science 2001, 294, 1102-1105.
65. Inoki, K.; Zhu, T.; Guan, K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115, 577-590.
66. Kimball, S.R.; Shantz, L.M.; Horetsky, R.L.; Jefferson, L.S. Leucine regulates translation of specific mRNAs in L6 myoblasts through mTOR-mediated changes in availability of eIF4E and phosphorylation of ribosomal protein S6. J. Biol. Chem. 1999, 274, 11647-11652.
67. Kenerson, H.L.; Aicher, L.D.; True, L.D.; Yeung, R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 2002, 62, 5645-5650.
68. Fingar, D.C.; Richardson, C.J.; Tee, A.R.; Cheatham, L.; Tsou, C.; Blenis, J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 2004, 24, 200-216.
69. Nguyen-Vu, P.A.; Fackler, I.; Rust, A.; DeClue, J.E.; Sander, C.A.; Volkenandt, M.; Flaig, M.; Yeung, R.S.; Wienecke, R. Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. J. Cutan. Pathol. 2001, 28, 470-475.
70. Brugarolas, J.B.; Vazquez, F.; Reddy, A.; Sellers, W.R.; Kaelin, W.G., Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003, 4, 147-158.
71. El-Hashemite, N.; Walker, V.; Zhang, H.; Kwiatkowski, D.J. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 2003, 63, 5173-5177.
72. Liu, M.Y.; Poellinger, L.; Walker, C.L. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res. 2003, 63, 2675-2680.
73. Moon, R.T.; Bowerman, B.; Boutros, M.; Perrimon, N. The promise and perils of Wnt signaling through beta-catenin. Science 2002, 296, 1644-1646.
74. Daniels, D.L.; Ekolf Spink, K.; Weis, W.I. Beta-catenin: molecular plasticity and drug design. Trends Biochem. Sci. 2001, 26, 672-678.
75. Miller, J.R.; Hocking, A.M.; Brown, J.D.; Moon, R.T. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene 1999, 18, 7860-7872.
76. Mak, B.C.; Takemaru, K.; Kenerson, H.L.; Moon, R.T.; Yeung, R.S. The tuberin-hamartin complex negatively regulates beta -catenin signaling activity. J. Biol. Chem. 2003, 278, 5947-5951.
77. Fukumoto, S.; Hsieh, C.M.; Maemura, K.; Layne, M.D.; Yet, S.F.; Lee, K.H.; Matsui, T.; Rosenzweig, A.; Taylor, W.G.; Rubin, J.S.; et al. Akt participation in the Wnt signaling pathway through Dishevelled. J. Biol. Chem. 2001, 276, 17479-17483.
78. Habas, R.; Kato, Y.; He, X. Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daaml. Cell 2001, 107, 843-854.
79. Marlow, F.; Topczewski, J.; Sepich, D.; Solnica-Krezel, L. Zebrafish Rho kinase 2 acts down-stream of Wnt11 to mediate cell polarity and effective convergence and extension movements. Curr. Biol. 2002, 12, 876-884.
80. Lamb, R.F.; Roy, C.; Diefenbach, T.J.; Vinters, H.V.; Johnson, M.W.; Jay, D.G.; Hall, A. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho [see comments]. Nat. Cell. Biol. 2000, 2, 281-287.
81. Astrinidis, A.; Cash, T.P.; Hunter, D.S.; Walker, C.L.; Chernoff, J.; Henske, E.P. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 2002, 21, 8470-8476.
82. Finlay, G.A.; Hunter, D.S.; Walker, C.L.; Paulson, K.E.; Fanburg, B.L. Regulation of PDGF production and ERK activation by estrogen is associated with TSC2 gene expression. Am. J. Physiol., Cell Physiol. 2003, 285, C409-C418.
83. Zhang, H.; Cicchetti, G.; Onda, H.; Koon, H.B.; Asrican, K.; Bajraszewski, N.; Vazquez, F.; Carpenter, C.L.; Kwiatkowski, D.J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 2003, 112, 1223-1233.
84. Henry, K.W.; Yuan, X.; Koszewski, N.J.; Onda, H.; Kwiatkowski, D.J.; Noonan, D.J. Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. J. Biol. Chem. 1998, 273, 20535-20539.
85. Birchenall-Roberts, M.C.; Fu, T.; Bang, O.S.; Dambach, M.; Resau, J.H.; Sadowski, C.L.; Bertolette, D.C.; Lee, HJ.; Kim, S.J.; Ruscetti, F.W. Tuberous sclerosis complex 2 gene product interacts with human SMAD proteins: a molecular link of two tumor suppressor pathways. J. Biol. Chem. 2004, 25605-25613.
86. Conery, A.C.Y.; Thompson, E.A.; Townsend, C.M.; Ko, T.C.; Luo, K. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-b-induced apoptosis. Nat. Cell. Biol. 2004, 6, 366-372.
87. Shah, O.J.; Hunter, T. Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex. J. Biol. Chem. 2004, 20816-20823.
88. Nellist, M.; Goedbloed, M.A.; De Winter, C.; Verhaaf, B.; Jankie, A.; Reuser, A.J.; Van Den Ouweland, A.M.; Van Der Sluijs, P.; Halley, D.J. Identification and characterization of the interaction between tuberin and 14-3-3zeta. J. Biol. Chem. 2002, 9, 9.
89. Li, Y.; Inoki, K.; Yeung, R.; Guan, K.L. Regulation of TSC2 by 14-3-3 binding. J. Biol. Chem. 2002, 277, 44593-44596.
90. Li, Y.; Inoki, K.; Vacratsis, P.; Guan, K.L. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J. Biol. Chem. 2003, 278, 13663-13671.
91. Shumway, S.D.; Li, Y.; Xiong, Y. 14-3-3beta binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin. J. Biol. Chem. 2003, 278, 2089-2092.
92. Soucek, T.; Yeung, R.S.; Hengstschlager, M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 15653-15658.
93. Fujita, N.; Sato, S.; Katayama, K.; Tsuruo, T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 2002, 277, 28706-28713.
94. Haddad, L.A.; Smith, N.; Bowser, M.; Niida, Y.; Murthy, V.; Gonzalez-Agosti, C.; Ramesh, V. The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton. J. Biol. Chem. 2002, 277, 44180-44186.
95. Astrinidis, A.; Senapedis, W.; Coleman, T.R.; Henske, E.P. Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J. Biol. Chem. 2003, 278, 51372-51379.
96. Roberg, K.J.; Bickel, S.; Rowley, N.; Kaiser, C.A. Control of amino acid permease sorting in the late secretory pathway of Saccharomyces cerevisiae by SEC13, LST4, LST7 and LST8. Genetics 1997, 147, 1569-1584.
97. Chen, E.J.; Kaiser, C.A. Amino acids regulate the intracellular trafficking of the general amino acid permease of Saccharomycescerevisiae. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 14837-14842.
98. Chen, E.J.; Kaiser, C.A. LST8 negatively regulates amino acid biosynthesis as a component of the TOR pathway. J. Cell. Biol. 2003, 161, 333-347.
99. Matsumoto, S.; Bandyopadhyay, A.; Kwiatkowski, D.J.; Maitra, U.; Matsumoto, T. Role of the Tsc1-Tsc2 complex in signaling and transport across the cell membrane in the fission yeast schizosaccharomyces pombe. Genetics 2002, 161, 1053-1063.
100. van Slegtenhorst, M.; Carr, E.; Stoyanova, R.; Kruger, W.D.; Henske, E.P. Tsc1+ and tsc2+ regulate arginine uptake and metabolism in Schizosaccharomyces pombe. J. Biol. Chem. 2004, 279, 12706-12713.
101. Kleymenova, E.; Ibraghimov-Beskrovnaya, O.; Kugoh, H.; Everitt, J.; Xu, H.; Kiguchi, K.; Landes, G.; Harris, P.; Walker, C. Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol. Cell 2001, 7, 823-832.
102. Hanaoka, K.; Qian, F.; Boletta, A.; Bhunia, A.K.; Piontek, K.; Tsiokas, L.; Sukhatme, V.P.; Guggino, W.B.; Germino, G.G. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 2000, 408, 990-994.
103. Conrad, P.A.; Smart, E.J.; Ying, Y.S.; Anderson, R.G.; Bloom, O.S. Caveolin cycles between plasma membrane caveolae and the Golgi complex by microtubule-dependent and microtubule-independent steps. J. Cell. Biol. 1995, 131, 1421-1433.
104. Eng, C. PTEN: one gene, many syndromes. Hum. Mutat. 2003, 22, 183-198.
105. Haruta, T.; Uno, T.; Kawahara, J.; Takano, A.; Egawa, K.; Sharma, P.M.; Olefsky, J.M.; Kobayashi, M. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol. Endocrinol. 2000, 14, 783-794.
106. Carlson, C.J.; White, M.F.; Rondinone, C.M. Mammalian target of rapamycin regulates IRS-I serine 307 phosphorylation. Biochem. Biophys. Res. Commun. 2004, 316, 533-539.
107. Shaw, R.J.; Kosmatka, M.; Bardeesy, N.; Hurley, R.L.; Witters, L.A.; DePinho, R.A.; Cantley, L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 3329-3335.
108. Lizcano, J.M.; Goransson, O.; Toth, R.; Deak, M.; Morrice, N.A.; Boudeau, J.; Hawley, S.A.; Udd, L.; Makela, T.P.; Hardie, D.G.; et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23, 833-843.
109. Hemminki, A.; Markie, D.; Tomlinson, I.; Avizienyte, E.; Roth, S.; Loukola, A.; Bignell, G.; Warren, W.; Aminoff, M.; Hoglund, P.; et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998, 391, 184-187.
110. Harris, T.E.; Lawrence, J.C., Jr. TOR signaling. Sci. STKE 2003, 2003, re15.
111. Oshiro, N.; Yoshino, K.; Hidayat, S.; Tokunaga, C.; Hara, K.; Eguchi, S.; Avruch, J.; Yonezawa, K. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 2004, 9, 359-366.
112. Podsypanina, K.; Lee, R.T.; Politis, C.; Hennessy, I.; Crane, A.; Puc, J.; Neshat, M.; Wang, H.; Yang, L.; Gibbons, J.; et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 10320-10325.
113. Neshat, M.S.; Mellinghoff, I.K.; Tran, C.; Stiles, B.; Thomas, G.; Petersen, R.; Frost, P.; Gibbons, J.J.; Wu, H.; Sawyers, C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/ mTOR. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 10314-10319.
114. Clark, G.J.; Kinch, M.S.; Rogers-Graham, K.; Sebti, S.M.; Hamilton, A.D.; Der, C.J. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J. Biol. Chem. 1997, 272, 10608-10615.
115. Lepourcelet, M.; Chen, Y.N.; France, D.S.; Wang, H.; Crews, P.; Petersen, F.; Bruseo, C.; Wood, A.W.; Shivdasani, R.A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004, 5, 91-102.
116. Dabora, S.L.; Roberts, P.; Nieto, A.; Perez, R.; Jozwiak, S.; Franz, D.; Bissler, J.; Thiele, E.A.; Sims, K.; Kwiatkowski, D.J. Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients. Am. J. Hum. Genet. 2002, 71, 750-758.